October 27, 2015
New Thomson Reuters Healthcare Intelligence Application to Streamline Industry Analysis for Financial Professionals
NEW YORK/LONDON – Thomson Reuters today announced the introduction of Healthcare Intelligence, a new application in Thomson Reuters Eikon that improves workflow for financial professionals by providing a one-stop location for information on current and in-development pharmaceutical products for a given indication. The Healthcare Intelligence app leverages content from Thomson Reuters Cortellis, the powerful intelligence platform for life science professionals.
The new app was developed by Thomson Reuters following discussions with healthcare financial research analysts. These discussions demonstrated a need for financial market and healthcare data to be embedded together to better determine market size and scope for particular indication or disease areas, such as diabetes, hypertension or cancers. Analysts typically collect and analyze drug pipeline information from many different sources, a process that can be fragmented, inefficient, and time-consuming. Thomson Reuters was able to respond rapidly to this need by developing an app that utilizes drug pipeline content from its intellectual property and life sciences business.
The Healthcare Intelligence app contains a dashboard view displaying the top companies by drug sales, and the number of drugs, deals, and active R&D pipelines for a specific indication/disease. The app also links to company pages that provide a summary of drug patents, drug development deals, clinical trials and other relevant information. For example, a key factor that analysts build into their research is the drug patent expiration date and how this event might affect the competitive landscape or a company’s stock price; this event information is now available through Healthcare Intelligence.
“By adding our Cortellis content into Eikon, Thomson Reuters is helping healthcare financial analysts to spend less time gathering and organizing data, and more time on analysis to drive their clients’ investment opportunities and decisions,” said Will Rowlands-Rees, global head of investment research, Thomson Reuters. “By drawing on content from across Thomson Reuters, this new application provides our customers with unique added value, demonstrating our on-going commitment to offering professionals the data and tools they need to find the answers they want.”
Additional information on the Healthcare Intelligence app and an accompanying video is available at https://youtu.be/L3q205nVslQ
Thomson Reuters Cortellis provides information on more than 61,000 drugs under development and 215,000 global clinical trials along with patent data, financial metrics and company profiles.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to http://thomsonreuters.com.